From Earlier: Zealand Pharma Announces That Its Partner Sanofi Has Applied for Regulatory Approval of Lixisenatide 1 for the Treatment of Type 2 Diabetes in Japan
Zealand Pharma A/S announces that its partner, Sanofi (NYSE: SNY), has submitted a marketing authorization application for lixisenatide (Lyxumia®) to Japan's Ministry of Health, Labour and Welfare. Lixisenatide is a once-daily investigational GLP-1 agonist, invented by Zealand Pharma and licensed to Sanofi for the treatment of Type 2 diabetes.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.